M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 50 of 54
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
NCT00075010
Smoking Cessation for HIV/AIDS Patients
NCT00502827
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
NCT00525785
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
NCT00504634
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
NCT00499343
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
NCT00429026
Natrecor in Pulmonary Hypertension
NCT00075179
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
NCT00506779
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
NCT00068432
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
NCT00082719
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
NCT00794820
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT00067639
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
NCT00067028
Pain Management Following TRAM Flap for Breast Reconstruction
NCT00500565
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
NCT00074750
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
NCT00506857
Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer
NCT00422500
The Effect of Donepezil on Sedation and Other Symptoms
NCT00352664
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
NCT00338728
Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer
NCT00500435
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
NCT00067808
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
NCT00412542
Busulfan and Fludarabine in Patients With AML and MDS
NCT00502905
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
NCT00336791
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT00346801
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
NCT00504660
Elizabeth Registry for Low Grade Ovarian Cancer
NCT00345709
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
NCT01538472
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
NCT00290433
Oral Valganciclovir Versus Valacyclovir
NCT00562770
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
NCT00506129
Letrozole in Patients With Ovarian Tumors
NCT00505661
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
NCT00503035
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
NCT00386373
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
NCT00338988
Rituximab Maintenance After Autologous Transplantation
NCT01103388
Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial
NCT05041946
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00500188
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
NCT00074763
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT00065143
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
NCT00283621
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
NCT00890656
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
NCT00500110
Wild Type p53 Adenovirus for Oral Premalignancies
NCT00410865
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
NCT00063258
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
NCT00062023
Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients
NCT00508846
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
NCT00084825
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
NCT00080678
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
NCT00063076
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.